New Effective Chemotherapy Regimen for Hodgkin’s Lymphoma

According to Italian researchers, a 7-drug chemotherapy regimen for advanced Hodgkin’s lymphoma can improve initial tumor control when compared with the typical regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

This team of researchers who conducted the research utilized in this study, headed up by Simonetta Viviani, MD, from the Milan Cancer Institute, published their results in the July 21 issue of the New England Journal of Medicine.
"Long-term outcome did not differ significantly between the 2 regimens," the authors wrote.

"If the goal is cure with the least overall toxic effects, the strategy of ABVD therapy — reserving rescue therapy with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation for patients in whom the primary treatment fails — must be favored," wrote Joseph Connors, MD, from the BC Cancer Agency Centre for Lymphoid Cancer in Vancouver, British Columbia.

"Initial ABVD wins hands down in terms of side effects," he said.

"Once cure is regularly being attained in the majority of patients and curative secondary treatment is available, the clinically valid comparison is between strategies of overall, not just primary, treatment," Connors wrote. "An apparently more effective initial treatment may be unattractive because of increased toxic effects."

More research had to be done on the topic before any definitive conclusions can be made.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap